Hernández-Valencia M, Hernández-Quijano T, Zárate A, Saucedo R

Language: Spanish
References: 11
Page: 705-708
PDF size: 67.22 Kb.

ABSTRACT

It has been accepted that preclinicall detection of breast cancer by means of the routine practice of mammography could discover the disease at its initial stage; therefore, practicing a mammography annually became widespread as a preventive health measure to diagnose the disease and prevent death due to breast cancer. Over time, the benefit of detection tests has been questioned and demonstration of their benefi t, as well as that of the undesirable effects they might cause, has been demanded. There is recent information with regard to an absence of difference in terms of breast cancer mortality as fi nal index between women with or without routine mammography. Additionally, a 20 % frequency has been observed in false-positive diagnoses, with high numbers of women undergoing unnecessary diagnostic procedures due to suspicion of a non-clinically apparent presumed cancer. In Mexico, from 2004 on, the popularity of mammography to detect and effectively cure cancer has increased. Acceptance can be attributted to how easily detection campaigns can be promoted, since most women accept that mastography can offer the opportunity of receiving an early treatment that reduces dissemination and prevents early mortality. The age at which it is convenient to perform the first mammography, how frequently it should be repeated and even the age for its discontinuation is still under debate and no consensus has been reached.

REFERENCES

1. Elmore JG, Harris RP. The harms and benefi ts of modern screening mammography. BMJ. 2014;348;g3824.

2. Habbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography, a cohort study. Ann Int Med. 2011;155(8):481-92.

3. Independ UK Panel on Breast Cancer Screening. The benefi ts and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855): 1778-86.

4. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty fi ve year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: Randomised screening trial. BMJ. 2014;348:g366. Disponible en http://www.bmj.com/ content/348/bmj.g366

5. Welch HG, Passow HJ. Quantifying the benefi ts and harms of screening mammography. JAMA Intern Med. 2014;174(3):448-54.

6. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605-13.

7. Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;6:CD001877. Published Online: 4 JUN 2013

8. Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A view from the Swiss medical board. NEJM. 2014;370(21):965-7.

9. Vesco KK, Whitlock EP, Eder M, Burda BU, Senger CA, LutzK. Risk factors and other epidemiologic considerations for cervical cancer screening: A narrative review for the U.S. Preventive Services Task Force. Ann Int Med. 2011;155(10):698-705.

10. Lieberman DA. Screening for colorectal cancer. N Engl J Med. 2009;361(12):1179-87.

11. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22): 2295-303.